SEARCH

SEARCH BY CITATION

References

  • 1
    Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States 1988–96. N Engl J Med 2000; 342: 605612.
  • 2
    Gourishankar S, Halloran PF. Late deterioration of organ transplants. a problem in injury and homeostasis. Curr Opin Immunol 2002; 14: 576583.
  • 3
    Knechtle SJ, Pirsch JD, Fechner Jr JH et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722730.
  • 4
    Kirk AD. Transplant tolerance: a look at the non-human primate literature in the view of modern tolerance theories. Crit Rev Immunol 1999; 19: 349388.
  • 5
    Baldwin WM 3rd, Larsen CP, Fairchild RL. Innate immune responses to transplants: a significant variable with cadaver donors. Immunity 2001; 14: 369376.
  • 6
    Li XC, Strom TB, Turka LA, Wells AD. T cell death and transplantation tolerance. Immunity 2001; 14: 407416.
  • 7
    Knechtle SJ, Vargo D, Fechner J et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997; 63: 16.
  • 8
    Calne R, Friend P, Moffatt S et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 17011702.
  • 9
    Swanson SJ, Hale DA, Mannon RB et al. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet 2002; 360: 16621664.
  • 10
    Kirk AD, Swanson SJ, Mannon RB et al. Preliminary results from a human tolerance trial using Campath-1H. Am J Transplant 2001; 1: S136.
  • 11
    Waldmann H. Transplantation tolerance-where do we stand? Nat Med 1999; 5: 12451248.
  • 12
    Kirk AD, Harlan DM. Challenges for the clinical application of transplant tolerance strategies. Curr Opin Organ Transplant 2000; 5: 108113.